Gyre Therapeutics (GYRE) Capital Expenditures (QoQ) (2010 - 2026)
Powered by 
Analysis
Gyre Therapeutics (GYRE) Capital Expenditures (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 47.19% |
| Mar 31, 2026 | 23.61% |
| Dec 31, 2025 | -75.55% |
| Sep 30, 2025 | 75.82% |
| Jun 30, 2025 | 174.59% |
| Mar 31, 2025 | 287.69% |
| Dec 31, 2024 | -109.38% |
| Sep 30, 2024 | -52.40% |
| Jun 30, 2024 | 530.30% |
| Mar 31, 2024 | -90.06% |
| Dec 31, 2023 | 17.73% |
| Sep 30, 2023 | -20.31% |
| Jun 30, 2023 | 42.19% |
| Sep 30, 2020 | 1,118.75% |
| Jun 30, 2020 | -5.88% |
| Mar 31, 2020 | 1,800.00% |
| Dec 31, 2019 | -200.00% |
| Sep 30, 2019 | -97.96% |
| Jun 30, 2019 | 226.67% |
| Mar 31, 2019 | -91.43% |